We are pleased to provide you with an introduction to each of our Visionary Plenary Sessions, beginning with MIND THE GAP: CROSSING THE FUNDING CHASM.
Chair: Bruce W Jenett, Senior Counsel, DLA Piper LLP (US)
- Gail Maderis, President & CEO, BayBio
- Pierre Meulien, Ph. D., President & CEO, Genome Canada
- Rajeev Dadoo, Ph. D., Partner, SR One
- Frank Gleeson, President & CEO, Gleeson and Associates, Executive in Residence, Ontario Institute for Cancer Research
- Mary E. Wheeler, Ph. D. (Invited), J&J Global Innovation Center, California
Life sciences is inherently a tough business, and a high-risk investment proposition, with huge cost and length of time necessary to bring most products to market, daunting regulatory hurdles, and the complexity of the science itself. Compounding that picture today are a number of disturbing events and trends, including reticence towards the industry by many investors, in both public and private capital markets, and a corresponding major shift in some parts of the venture capital industry, the lack of public market liquidity, escalating new product discovery costs, and the like.
What do these trends and events mean for the industry, and the position of Canada and the United States in the global market and in science leadership, in the creation of new drugs, devices and analytical instruments? Will the industry shrink further? Will it survive? Is this just a normal periodic settling out of the industry or is it an alarming trend? Will Canada and the U.S. continue to be the center of the industry or will we lose leadership to countries willing to pour money into the industry?
This panel of experts tackle these issues with a hard-hitting and realistic “think-tank” approach. Expect a lively interactive discussion about what’s going on now – and what can be expected in the future and what it all means for your company, and the industry as a whole.
Watch for additional program updates later this week!
BioPartnering North America | February 24-26, 2013 | Vancouver, BC